Study |
N |
Design |
Inclusion Criteria |
Average Length of follow-up |
Outcomes Evaluated |
Results |
Comments |
OBSERVATIONAL STUDIES
|
|
|
|
|
|
|
|
Yazu, 200031
|
42 |
Prospective observational |
Contraindication to anticoagulation, recurrent VTE on anticoagulation, other prophylactic purposes |
35 months |
Complications |
5% developed symptomatic PE 5% developed asymptomatic PE PE is 16.7% of those who did not receive anticoagulation and 7.4% of those who received anticoagulation |
Lowe rates of PE and filter captured thrombus in those on concurrent anticoagulation |
Johnson, 201032
|
100 |
Prospective single arm clinical trial evaluating safety and effectiveness of retrievable option IVC filer |
Pulmonary thromboembolism when anticoagulation is contraindicated, failure of anticoagulant therapy in thromboembolic disease (TED), complication of anticoagulation therapy for TED or indication for temporary filter (bariatric surgery or trauma) |
180 days For those who had filter removed 30 days after filter removal |
"Clinical success"- technical success without subsequent PE, significant filter migration or embolization, symptomatic cava thrombosis or other complications |
8 cases of recurrent PE, two cases of filter migration, no filter embolization or fracture Clinical success in 88% of participants 39 subjects had attempted Retrieval successful for 92% patients at a mean of 67 days 17 deaths and 18 DVT were judged not related to filter |
No comparison group |
Imberti, 20058
|
30 |
Prospective observational multi-center of ALN retrievable IVC filter |
VTE with a contraindication to anticoagulation, primary prophylaxis after major trauma or before surgery in patients with high thromboembolic risk |
18.2 months |
Efficacy and likelihood of filter removal |
3 cases of trapped emboli in filter 1 case asymptomatic filter migration toward heart 2 DVT recurrences ALN removal attempted in 18 patients and successful in 78% Retrieval less successful more than 3 months after implantation Median implantation 123 days |
Retrieval safe and efficacious after medium period of placement Retrieval more than three months after placement less successful |
Ziegler, 200833
|
150 |
Post-marketing surveillance; multicenter prospective of OptEase IVC filter as permanent filter |
PE with anticoagulation contraindicated; anticoagulation failure, emergency treatment after massive PE, chronic and or recurrent PE where anticoagulation failed or was contraindicated and patients at high risk for PE with relative or absolute contraindication to anticoagulation |
Six months |
Primary endpoints: filter migration and symptomatic thrombosis one month after implantation Secondary endpoints: major adverse events, filter tilting |
At one month 0.9% filter migration and 0.9% filter thrombosis No new filter migration or symptomatic thrombosis at 6 months |
55 out of 150 did not complete full six month evaluation |
Bovyn, 200634
|
103 |
Multicenter prospective study of patients receiving Tempofilter II |
Complications of or contraindications to anticoagulation therapy, ineffectiveness of anticoagulation therapy or prophylactic (high risk surgery or free floating thrombus) |
90 days |
Rate of retrieval Filter related complications PE |
Filter in place for a mean of 29.5 days All filters except one were removed One episode of filter migration followed by PE |
Filter retrieval successful when filter in place for relatively short period |
Ricco, 199541
|
222 |
Multicenter prospective |
PE on anticoagulation PE with contraindication to anticoagulation PE and ileocaval thrombosis Ileocaval/femoral or popliteal thrombosis Thrombosis without embolism Cor pulmonale with lower extremity thrombosis |
15 months |
Local complications General complications |
1.7% 30 day mortality 2.2% recurrent PE 3.6% filter migration Two recurrent PE Seven caval thromboses |
|
Mismetti, 200736
|
220 |
Single center prospective cohort of patients with retrievable VCF |
Recurrent VTE despite anticoagulation, transient bleeding event, definite contraindication to anticoagulation or need to stop anticoagulation due to major surgery trauma or invasive procedure |
18 months |
Success of filter insertion Clinical events related to filter insertion Filter retrieval |
Filter insertion 98.6% successful Complication of filter placement 11.8% Median duration of filter placement 166 days At least one VTE 17% Removal successful at first attempt in 92.7% of patients
|
Largest multicenter study of single type of retrievable filter |
Greenfield, 199137
|
186 |
Prospective multi-center study of modified hook-titanium Greenfield filter |
Contraindication to anticoagulation Free floating thrombus, anticoagulation complication Anticoagulation failure Recurrent embolism with pulmonary hypertension Massive embolism requiring vasopressors |
30 day |
Safety and efficacy |
97% filter placement success 22 deaths from PE 9.75 new lower extremity edema No filter occlusion |
Study goal was to evaluate modified filter |
TRIALS
|
|
|
|
|
|
|
|
Fullen, 1973 J or Trauma 1973;13: 403–10)38
|
129 |
Single center trial Participants received permanent cava filter or no filter |
Proximal femoral fracture |
33 days |
Mortality PE Filter insertion complications |
No difference in mortality Fewer PE in filter group (RR 0.3; 95% C.I. 0.11,.0.82) |
No information on long term complications |
Decousus, 199839; PREPIC, 200542
|
400 |
Randomized controlled trial (RCT) with 2 x 2 factorial design also comparing low molecular weight heparin to unfractionated heparin |
Acute DVT with or without PE and if physicians considered them to be at high risk for PE |
2 year and 8 year |
Recurrent VTE, death and major bleeding |
At day 12, fewer PE in the filter group than in the no filter group (OR 0.22: 95% C.I. 0.05, 0.90) At two years more recurrent DVT in filter group (OR 1.87: 95% C.I. 1.10, 3.20) Similar results at one year follow up |
|
Usoh, 201040
|
156 (N=84 Greenfield and n=72 Trapease) |
Prospective randomized comparative study comparing IVC Greenfield and TrapEase filters |
Contraindication to anticoagulation, or failed anticoagulation, high risk trauma patient or high risk procedure with history of VTE |
12 months |
Access site thrombosis Filter thrombosis Symptomatic PE |
Symptomatic IVC/IV thrombosis in 6.94% in the TrapEase group and none in the Greenfield group (P=0.19) No filter migration, access site thrombosis misplacement or IVC perforation Recurrent PE suspected in one of five patients with IVC/IV thrombosis 30 day and 12 month mortality was comparable between the two groups |
349 eligible patients during the time period did not participate in the study. Higher rate of IVC/IV thrombosis in those who received TrapEase- effect was not related to anticoagulation |
Comments